Search results for "immunosuppressive agent"

showing 10 items of 282 documents

Immunosuppressant therapy of thyroid eye disease.

1988

Thyroid eye disease is attributed to an autoimmune process where both cellular and humoral immunity play a role. In this report, after a short introduction dealing with immunopathogenesis of the disease, immunosuppressant therapy is discussed. Treatment with glucocorticoids (as the standard substance), nonsteroid immunosuppressants (azathioprine, cyclophosphamide, lately cyclosporin) and with the immunomodulatory substance ciamexone is reviewed. Retroorbital irradiation as a "local" immunosuppressive method and plasmapheresis are also discussed. While systemic glucocorticoids and to a lesser extent orbital radiotherapy are routinely administered for severe Graves' ophthalmopathy, nonsteroid…

Immunosuppression TherapyCyclophosphamidebusiness.industrymedicine.medical_treatmentEye diseaseThyroidAzathioprineGeneral MedicineDiseasemedicine.diseaseeye diseasesGraves DiseaseRadiation therapymedicine.anatomical_structureAutoimmune ProcessDrug DiscoveryImmunologymedicineMolecular MedicineHumansPlasmapheresisbusinessGenetics (clinical)Immunosuppressive Agentsmedicine.drugKlinische Wochenschrift
researchProduct

In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.

2007

The objective was to devise and apply a novel modelling approach to combine segmental in situ rat perfusion data and in vitro cell culture data, in order to elucidate the contribution of efflux in drug absorption kinetics. The fluoroquinolone CNV97100 was used as a model P-gp substrate. In situ intestinal perfusion was performed in rat duodenum, jejunum, ileum and colon to measure the influence of P-gp expression on efflux. Inhibition studies of CNV97100 were performed in the presence of verapamil, quinidine, cyclosporin A and p-aminohippuric acid. Absorption/efflux parameters were modelled simultaneously, using data from both in situ studies as well as in vitro studies. The maximal efflux …

In situAbsorption (pharmacology)MaleColonVasodilator AgentsPharmaceutical ScienceIleumMuscarinic AntagonistsModels BiologicalIntestinal absorptionPermeabilityJejunumCiprofloxacinCyclosporin aIntestine SmallmedicineAnimalsPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Intestinal MucosaRats WistarP-glycoproteinPharmacologybiologyDose-Response Relationship DrugMolecular StructureChemistryGeneral MedicineQuinidineRatsKineticsmedicine.anatomical_structureBiochemistryIntestinal AbsorptionVerapamilbiology.proteinBiophysicsCyclosporinep-Aminohippuric AcidEffluxAlgorithmsImmunosuppressive AgentsFluoroquinolonesBiopharmaceuticsdrug disposition
researchProduct

First clinical uterus transplantation trial: a six-month report.

2014

Objective To report the 6-month results of the first clinical uterus transplantation (UTx) trial. This type of transplantation may become a treatment of absolute uterine-factor infertility (AUFI). Design Prospective observational study. Setting University hospital. Patient(s) Nine AUFI women and their live uterine donors, the majority being mothers. Intervention(s) Live-donor UTx and low-dose induction immunosuppression. Main Outcome Measure(s) Data from preoperative investigations, surgery and follow-up for 6 months. Result(s) Durations of donor and recipient surgery ranged from 10 to 13 hours and from 4 to 6 hours, respectively. No immediate perioperative complications occurred in any of …

InfertilityAdultGraft Rejectionmedicine.medical_specialtymedicine.drug_classUterusABO Blood-Group SystemCohort Studiesmedicine.arteryUterus transplantationMedicineHumansProspective StudiesUterine arterybusiness.industryUterusObstetrics and GynecologyPerioperativeMiddle Agedmedicine.diseaseSurgeryClinical trialTransplantationmedicine.anatomical_structureReproductive MedicineBlood Group IncompatibilityTissue TransplantationCorticosteroidFeasibility StudiesFemalebusinessInfertility FemaleImmunosuppressive AgentsFollow-Up StudiesFertility and sterility
researchProduct

Potassium regulates IL-1 beta processing via calcium-independent phospholipase A2.

2000

Abstract We report that potassium leakage from cells leads to activation of the Ca2+-independent phospholipase A2 (iPLA2), and the latter plays a pivotal role in regulating the cleavage of pro-IL-1β by the IL-converting enzyme caspase-1 in human monocytes. K+ efflux led to increases of cellular levels of glycerophosphocholine, an unambiguous indicator of phospholipase A2 activation. Both maturation of IL-1β and formation of glycerophosphocholine were blocked by bromoenol lactone, the specific iPLA2 inhibitor. Bromoenol lactone-dependent inhibition of IL-1β processing was not due to perturbation of the export machinery for pro-IL-1β and IL-1β or to caspase-1 suppression. Conspicuously, activ…

Intracellular FluidPotassiumImmunologychemistry.chemical_elementNaphthalenesCleavage (embryo)MonocytesPhospholipases APhospholipase A2Calcium-Independent Phospholipase A2Immunology and AllergyHumansCells Culturedchemistry.chemical_classificationCalcium metabolismbiologyTumor Necrosis Factor-alphaCaspase 1Biological TransportCaspase InhibitorsCell biologyEnzyme ActivationPhospholipases A2EnzymechemistryPyronesbiology.proteinPotassiumCalciumEffluxBromoenol lactoneProtein Processing Post-TranslationalImmunosuppressive AgentsInterleukin-1Journal of immunology (Baltimore, Md. : 1950)
researchProduct

T Cell Large Granular Lymphocytic Leukemia in Association with Sjögren’s Syndrome

2009

T cell large granular lymphocytic (LGL) leukemia is a rare condition accounting for 2–3% of all mature lymphoid leukemias. Here, we present the case of a 73-year-old woman presenting with neutropenia and anemia (hemoglobin 9.9 g/dl). Hematological assessment revealed the presence of a T cell LGL leukemia. At the time of T cell LGL leukemia diagnosis, the patient developed xerophthalmia and xerostomia, and a diagnosis of Sjögren’s syndrome was made following salivary gland biopsy. The finding of large granular lymphocytes in the context of autoimmune disorders is well-known, though it often occurs with rheumatoid arthritis or in association with a positive autoantibody titer in the absence o…

LGL leukemiaNeutropeniaT cellchemical and pharmacologic phenomenaContext (language use)Settore MED/08 - Anatomia PatologicaNeutropeniamedicine.disease_causeAutoimmune DiseasesSettore MED/15 - Malattie Del SangueAutoimmunityhemic and lymphatic diseasesmedicineHumansAgedbusiness.industryAutoantibodyAnemiaHematologyGeneral Medicinemedicine.diseaseLymphomaLeukemia Large Granular LymphocyticLeukemiaSjogren's Syndromemedicine.anatomical_structureRheumatoid arthritisImmunologyFemalebusinessImmunosuppressive AgentsActa Haematologica
researchProduct

Pharmacogenetic Study of ABCB1 and CYP3A5 Genes During the First Year Following Heart Transplantation Regarding Tacrolimus or Cyclosporine Levels

2011

Pharmacogenetics explains part of the interindividual variability in drug responses. Many published works about the effects of single nucleotide polymorphisms (SNPs) on immunosuppressive drug blood levels present contradictory results. We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. One blood sample was obtained from each of 41 patients: 26 treated with cyclosporine and 15 with tacrolimus. We characterize the SNPs rs1045642, 1128503, 2032582, 2235013, 2235033, 2229109, 3213619, 9282564 in ABCB1 and rs10264272, 776746 in CYP3A5 genes using the …

Linkage disequilibriummedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentSingle-nucleotide polymorphismBiologyPharmacologyPolymorphism Single NucleotideGastroenterologyLinkage DisequilibriumTacrolimusGene FrequencyInternal medicineGenotypemedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1CYP3A5Heart transplantationTransplantationTacrolimusPhenotypeImmunosuppressive drugPharmacogeneticsSpainCyclosporineHeart TransplantationSurgeryDrug MonitoringImmunosuppressive AgentsPharmacogeneticsTransplantation Proceedings
researchProduct

Budlein A from Viguiera robusta inhibits leukocyte-endothelial cell interactions, adhesion molecule expression and inflammatory mediators release

2009

Budlein A has been reported to exert some analgesic and anti-inflammatory properties. In this study, we have evaluated its effect on LPS-induced leukocyte recruitment in vivo and the mechanisms involved in its anti-inflammatory activity. In vivo, intravital videomicroscopy was used to determine the effects of budlein A on LPS-induced leukocyte-endothelial cell interactions in the murine cremasteric microcirculation. In vitro, the effects of budlein A on LPS-induced cytokine, chemokine and nitrites release, T-cell proliferative response as well as cell adhesion molecule expression (CAM) were evaluated. In vivo, intraperitoneal administration of budlein A (2.6 mM/kg) caused a significant redu…

LipopolysaccharidesMaleChemokineT-Lymphocytesmedicine.medical_treatmentPharmaceutical ScienceLeukocyte RollingCell CommunicationAsteraceaeNitric OxideDexamethasoneCell LineLactonesMiceIn vivoDrug DiscoverymedicineAnimalsHumansLeukocyte RollingInterleukin 8NitritesCell ProliferationPharmacologyMice Inbred BALB CbiologyPlant ExtractsCell adhesion moleculeMacrophagesMicrocirculationMonocyteEndothelial CellsCell biologyMice Inbred C57BLEndothelial stem cellmedicine.anatomical_structureCytokineComplementary and alternative medicinebiology.proteinMolecular MedicineChemokinesCell Adhesion MoleculesSesquiterpenesImmunosuppressive AgentsPhytomedicine
researchProduct

Inflammatory Characteristics of Monocytes from Pediatric Patients with Tuberous Sclerosis.

2015

Objective  Therapeutic options for the tuberous sclerosis complex (TSC) syndrome showed varying outcomes. Malfunctional tsc1 / tsc2 genes leave mTOR uninhibited, a positive downstream modulator of the innate proinflammatory immune system, which has not yet been described in pediatric patients with TSC. Methods  Using polymerase chain reaction (PCR) gene expression levels of monocytes after cultivation with lipopolysaccharide (LPS) or with LPS + mTOR inhibitor rapamycin, patients with TSC ( n  = 16) were compared with healthy subjects ( n  = 20). Results  Compared with monocytes from healthy controls, LPS showed a more prominent gene expression pattern in patients with TSC (CCL24, CXCL10, IL…

Lipopolysaccharidescongenital hereditary and neonatal diseases and abnormalitiesLipopolysaccharideGene ExpressionMonocytesProinflammatory cytokinechemistry.chemical_compoundTuberous sclerosisTuberous SclerosisGene expressionmedicineCXCL10HumansChildInflammationSirolimusbusiness.industryTOR Serine-Threonine KinasesInfant NewbornInfantGeneral Medicinemedicine.diseasemedicine.anatomical_structureCross-Sectional StudieschemistryChild PreschoolPediatrics Perinatology and Child HealthImmunologyCytokinesNeurology (clinical)TSC1TSC2Inflammation MediatorsbusinessCCL24Immunosuppressive AgentsNeuropediatrics
researchProduct

Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir.

2013

Haemophagocytic syndrome (HS) is a rare disease that is often fatal despite treatment. HS is characterized by fevers, lymphadenopathy, hepatosplenomegaly, cytopenias and hyperferritinaemia due to deregulated activation and proliferation of macrophages, leading to uncontrolled phagocytosis of platelets, erythrocytes, lymphocytes, and their hematopoietic precursors throughout the reticuloendothelial system. Mycobacterium tuberculosis-associated HS is a rare and underdiagnosed association with only 39 cases reported. We describe a case of HS associated with disseminated Mycobacterium tuberculosis in the setting of post-liver transplantation anti-hepatitis C therapy with pegylated interferon (p…

Liver CirrhosisMaleTuberculosisTime Factorsmedicine.medical_treatmentHepatosplenomegalyAntitubercular AgentsSpecialties of internal medicineHepacivirusLiver transplantationVHCAntiviral AgentsLymphohistiocytosis HemophagocyticTelaprevirTelaprevirchemistry.chemical_compoundFatal OutcomePegylated interferonRisk FactorsmedicineHumansTuberculosisHepatologyHaemophagocytic syndromebusiness.industryRibavirinGeneral MedicineMycobacterium tuberculosisMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationTransplantationchemistryRC581-951ImmunologyDrug Therapy CombinationVirus Activationmedicine.symptombusinessOligopeptidesImmunosuppressive Agentsmedicine.drugRare diseaseAnnals of hepatology
researchProduct

Early Steroid-Free Immunosuppression With FK506 After Liver Transplantation: Long-Term Results of a Prospectively Randomized Double-Blinded Trial

2010

Background. The aim of this prospective, randomized, double-blinded, placebo-controlled single center study was to evaluate an early steroid-free immunosuppression in liver transplant patients. Methods. From March 2000 to October 2004, 110 patients were included. All patients received tacrolimus and steroids during the first 2 weeks after orthotopic liver transplantation (OLT). Thereafter, patients in the steroid group (n=54) received steroids and the remaining 56 a placebo. After 6 months, the immunosuppression for all was steroid free. Thirty patients were hepatitis C positive. Five years after inclusion, patient survival, organ survival, steroid side effects, and recirrhosis in hepatitis…

Liver Cirrhosismedicine.medical_specialtyTime Factorsmedicine.medical_treatmentHypercholesterolemiaLiver transplantationSingle CenterPlaceboGastroenterologyTacrolimusPostoperative ComplicationsDouble-Blind MethodAdrenal Cortex HormonesRecurrenceInternal medicineDiabetes MellitusmedicineHumansSurvival rateAntibacterial agentTransplantationDose-Response Relationship Drugbusiness.industryGraft SurvivalImmunosuppressionHepatitis Cmedicine.diseaseHepatitis CTacrolimusLiver TransplantationSurgerySurvival RateTreatment OutcomebusinessImmunosuppressive AgentsTransplantation
researchProduct